Antioxidant-mediated inflammatory pathway regulation (None widely established)

Antioxidant-mediated inflammatory pathway regulation represents a complex biological mechanism where antioxidant activity directly influences inflammatory signaling cascades. This target encompasses several interconnected molecular pathways that link oxidative stress with inflammation. The Keap1/Nrf2/ARE pathway is a central component of this target, representing one of the most important cellular defense mechanisms against oxidative stress and xenobiotic damage[2]. Under normal conditions, Nrf2 is sequestered in the cytosol by Keap1, but oxidative stress disrupts this interaction, allowing Nrf2 to translocate to the nucleus where it activates antioxidant response element (ARE)-dependent gene expression[2]. This leads to the production of antioxidative and cytoprotective proteins that counteract inflammation. A critical aspect of this target is the antagonistic relationship between Nrf2 and NF-κB pathways. While Nrf2 promotes antioxidant responses, NF-κB drives inflammatory processes. Activation of Nrf2 has been shown to counteract NF-κB-driven inflammatory responses in various experimental models[2]. For example, when Nrf2 upregulates heme oxygenase-1 (HO-1) expression, it reduces NF-κB inflammatory activity and shifts cells to a more reducing environment that helps terminate NF-κB activation[2]. The inflammatory process itself involves complex cellular mechanisms. During inflammation, leukocytes and mast cells present in damaged regions undergo a "respiratory burst," increasing oxygen uptake and producing reactive oxygen species (ROS)[1]. Inflammatory cells also generate soluble inflammatory mediators like cytokines, arachidonic acid, and chemokines, which activate more inflammatory cells and release more reactive species[1]. These markers stimulate signal transduction cascades and alter transcription factors including NF-κB, leading to the expression of pro-inflammatory enzymes like cyclooxygenase-2 (COX-2) and inflammatory cytokines such as TNF-α and IL-1β[1]. Lipid mediators play a significant role in this target. Pro-resolving lipid mediators like lipoxin A4 (LXA4) and Resolvin D1 (RvD1) have been shown to diminish inflammation via Nrf2 activation[4]. Similarly, omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) exhibit cytoprotective effects against oxidative insults in a Nrf2-dependent manner[4]. Compounds like astaxanthin demonstrate how this target can be therapeutically modulated. Astaxanthin protects cell membranes against reactive oxygen and nitrogen species (RONS) through its unique chemical structure and positioning within cell membranes[6]. It inhibits the NF-κB and MAPK signaling pathways, suppressing inflammatory processes and stimulating reverse cholesterol transport, which attenuates the formation of foam cells involved in cardiovascular disease[6]. Recent research has shown promising applications of this target in managing various inflammatory diseases, including bacterial infections, arthritis, inflammatory bowel disease, and cancer[5]. The therapeutic potential lies in the ability to modulate inflammation by targeting oxidative stress pathways, offering new avenues for developing preventive and therapeutic strategies.

Other names

Oxidative stress-inflammatory response axisRedox-sensitive inflammatory signalingAntioxidant-inflammation crosstalk

Activation of Nrf2/ARE pathway; Inhibition of NF-κB signaling; Suppression of pro-inflammatory cytokines; Reduction of reactive oxygen and nitrogen species (RONS); Modulation of MAPK signaling; Enhancement of endogenous antioxidant enzyme activity